A new contact lens that elutes antihistamine has been approved by the US Food and Drug Administration as a treatment for ocular allergies. FDA Approvals
Tag: News Alert
FDA Approves Faricimab for nAMD and Diabetic Macular Edema
The US Food and Drug Administration has approved faricimab, a drug with the potential to reduce the number of injections needed to treat diabetic macular edema and neovascular age-related macular degeneration. FDA Approvals
Novel Drug, First Tx for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival. FDA Approvals
Novel Drug, First Tx Approved for Rare Uveal Melanoma
A novel drug, the first in its class, is also the first treatment approved for use in uveal melanoma, a rare cancer of the eye, after it was shown to improve overall survival. FDA Approvals
FDA Approves Eye Drops for Presbyopia
The first topical preparation to treat presbyopia — farsightedness caused by loss of elasticity of the lens of the eye, typically occurring in middle and old age — has won approval from the FDA. FDA Approvals
FDA Approves Drugs for Wet AMD, Macular Edema Due to Uveitis
Wet AMD gets Susvimo, an intravitreal ranibizumab injection, and macular edema gets Xipere, a triamcinolone acetonide injectable suspension. FDA Approvals
FDA Approves First Nasal Spray for Dry Eye
The FDA has approved the first-ever nasal spray to treat dry eye disease. It provides an alternative to immunomodulators. FDA Approvals
FDA Approves Ranibizumab Biosimilar
Byooviz has the potential to be less expensive than Lucentis, the reference product. FDA Approvals
2021 Match Sets Records: Who Matched and Who Didn’t?
Despite COVID upending the process, the NRMP reports record numbers, with total and first-year positions both up from 2020. Fill rates increased across the board, even as some candidates missed out. Medscape Medical News
EMA Warns of Eylea Injection Risk
News Alerts
FDA Approves Added Safety Info for Brolucizumab (Beovu) Label
The FDA approved the addition of safety information about the risk for retinal vasculitis and/or retinal vascular occlusion in patients receiving the drug. News Alerts
More Medical Conferences Fall to Coronavirus
Several more meetings join the list of those that have canceled or postponed. Medscape Medical News
FDA OKs First Biodegradable Implant to Lower IOP
Bimatoprost implant (Durysta) delivers 10 µg of the prostaglandin analog and is an alternative to daily topical eye drops in patients with open-angle glaucoma or ocular hypertension. FDA Approvals
FDA OKs First Generic of Daraprim (Pyrimethamine) Tablets
Generic pyrimethamine, from Cerovene Inc, is indicated for the treatment of toxoplasmosis when used with a sulfonamide. FDA Approvals
FDA Approves First Treatment for Thyroid Eye Disease
The monoclonal antibody teprotumumab reduces proptosis and related eye problems in patients with thyroid-associated ophthalmopathy. FDA Approvals
FDA OKs Ophthalmic Stain for Vitreoretinal Surgery
Brilliant Blue G (0.025%) ophthalmic solution selectively stains the internal limiting membrane to distinguish it from the retina to facilitate removal. FDA Approvals
Brolucizumab Gets EU Panel Backing for Wet AMD
The treatment, previously approved by the FDA, offers less-frequent injections, and efficacy proven in two head-to-head global trials. International Approvals
FDA OKs First Contact Lens to Slow Myopia in Children
MiSight (CooperVision Inc) soft, disposable contact lenses are meant to be worn daily (but not overnight) to correct nearsightedness and slow the progression of myopia in children 8 to 12 years old. FDA Approvals
FDA Approves New Injection Brolucizumab (Beovu ) for Wet AMD
The US Food and Drug Administration approved brolucizumab (Beovu, Novartis) injection for wet age-related macular degeneration (AMD). FDA Approvals
EMA Panel Backs Netarsudil for Elevated Intraocular Pressure
An EMA advisory panel recommended marketing authorization for netarsudil ophthalmic solution 0.02% for the treatment of adults with glaucoma or ocular hypertension. International Approvals